{Reference Type}: Case Reports
{Title}: Case Report: Two cases of advanced primary cardiac angiosarcoma treated with anlotinib and a retrospective analysis of the literature.
{Author}: Yang P;Xiong F;Zhu B;Gong L;Tang C;
{Journal}: Front Cardiovasc Med
{Volume}: 11
{Issue}: 0
{Year}: 2024
{Factor}: 5.846
{DOI}: 10.3389/fcvm.2024.1363235
{Abstract}: Primary cardiac angiosarcoma is a rare malignant soft-tissue sarcoma derived from vascular endothelial cells or lymphatic endothelial cells, with a high malignancy, poor prognosis, and a lack of effective medical therapy. This article reports on two patients with primary cardiac angiosarcoma who received first-line treatment with multi-targeted anti-angiogenic agent, anlotinib monotherapy. The treatment rapidly controlled pleural and pericardial effusion, significantly reduced the tumor, improved symptoms, and showed satisfactory recent efficacy. This indicates that anlotinib offers a new first-line treatment option for advanced primary cardiac angiosarcoma.